RxDoctor Payments DataLook up a doctor →

Paul Boyce

Pulmonary Disease · Atlanta, GANPI 1912988445

Payments from drug & device makers

$405,680in general payments, 2019–2025

Across 333 payments — averaging $1218.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$187K
  • Janssen Research & Development, LLC$126K
  • Karyopharm Therapeutics Inc.$52K
  • Genentech, Inc.$29K
  • Actelion Pharmaceuticals US, Inc.$4K
  • Sanofi Pasteur Inc.$2K
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$2,72523%
  • Speaking & faculty fees$2,46921%
  • Travel & lodging$420%
  • Food & beverage$6,52955%
  • Education$911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$405,680 in reported general payments places this provider in the 95th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$81,652
Medicare patients
310
Services billed
821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter161$114,956
Tadalafil25$16,512
Breo ElliptaFluticasone/Vilanterol22$12,251
EliquisApixaban16$10,472
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$9,970
Advair HfaFluticasone Propion/Salmeterol16$8,285
SymbicortBudesonide/Formoterol Fumarate21$6,905
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$2,300
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,770
Albuterol Sulfate HfaAlbuterol Sulfate80$1,663
Wixela InhubFluticasone Propion/Salmeterol16$1,481
Cefdinir17$381
Prednisone47$186
Potassium Chloride11$175
Methylprednisolone21$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$791$137,177199 claims
PfizerEliquis$39$10,47216 claims
AstraZenecaSymbicort$678$6,90521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →